Literature DB >> 17009917

Early diagnostics and therapeutics for Alzheimer's disease--how early can we get there?

Bernhard H Monien1, Liana G Apostolova, Gal Bitan.   

Abstract

Alzheimer's disease (AD) is a major threat for the rapidly aging world population. AD is the leading cause of dementia and a major cause of death in developed countries. The disease puts a tremendous practical, emotional and financial burden on individuals and governments. Clinicians and researchers in the AD field face great challenges: the pathophysiological processes that cause AD are not well understood, definite diagnosis of AD requires autopsy, and therapeutic options are limited to treating the symptoms rather than the cause of the disease. Nevertheless, new insights into the earliest events that lead to development of AD increase hope that reliable diagnostics and efficacious therapies may emerge.

Entities:  

Mesh:

Year:  2006        PMID: 17009917      PMCID: PMC2715564          DOI: 10.1586/14737175.6.9.1293

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  131 in total

Review 1.  Alzheimer's disease: the amyloid cascade hypothesis.

Authors:  J A Hardy; G A Higgins
Journal:  Science       Date:  1992-04-10       Impact factor: 47.728

2.  Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis.

Authors:  C S Atwood; R D Moir; X Huang; R C Scarpa; N M Bacarra; D M Romano; M A Hartshorn; R E Tanzi; A I Bush
Journal:  J Biol Chem       Date:  1998-05-22       Impact factor: 5.157

3.  Ubiquitin is a component of paired helical filaments in Alzheimer's disease.

Authors:  H Mori; J Kondo; Y Ihara
Journal:  Science       Date:  1987-03-27       Impact factor: 47.728

4.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

5.  Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.

Authors:  C A Lemere; J K Blusztajn; H Yamaguchi; T Wisniewski; T C Saido; D J Selkoe
Journal:  Neurobiol Dis       Date:  1996-02       Impact factor: 5.996

6.  Disaggregation of Alzheimer beta-amyloid by site-directed mAb.

Authors:  B Solomon; R Koppel; D Frankel; E Hanan-Aharon
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

7.  Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology.

Authors:  Salvatore Oddo; Antonella Caccamo; Levina Tran; Mary P Lambert; Charles G Glabe; William L Klein; Frank M LaFerla
Journal:  J Biol Chem       Date:  2005-11-10       Impact factor: 5.157

Review 8.  Transgenic models of Alzheimer's disease: learning from animals.

Authors:  Tara L Spires; Bradley T Hyman
Journal:  NeuroRx       Date:  2005-07

9.  Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions.

Authors:  D A Bennett; J A Schneider; J L Bienias; D A Evans; R S Wilson
Journal:  Neurology       Date:  2005-03-08       Impact factor: 9.910

10.  Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease.

Authors:  G B Karas; P Scheltens; S A R B Rombouts; P J Visser; R A van Schijndel; N C Fox; F Barkhof
Journal:  Neuroimage       Date:  2004-10       Impact factor: 6.556

View more
  6 in total

1.  Selection of aptamers for amyloid beta-protein, the causative agent of Alzheimer's disease.

Authors:  Farid Rahimi; Gal Bitan
Journal:  J Vis Exp       Date:  2010-05-13       Impact factor: 1.355

Review 2.  Brain mapping as a tool to study neurodegeneration.

Authors:  Liana G Apostolova; Paul M Thompson
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

3.  Raman spectroscopy of blood serum for Alzheimer's disease diagnostics: specificity relative to other types of dementia.

Authors:  Elena Ryzhikova; Oleksandr Kazakov; Lenka Halamkova; Dzintra Celmins; Paula Malone; Eric Molho; Earl A Zimmerman; Igor K Lednev
Journal:  J Biophotonics       Date:  2014-09-25       Impact factor: 3.207

4.  Surface feature-guided mapping of cerebral metabolic changes in cognitively normal and mildly impaired elderly.

Authors:  Liana G Apostolova; Paul M Thompson; Steve A Rogers; Ivo D Dinov; Charleen Zoumalan; Calen A Steiner; Erin Siu; Amity E Green; Gary W Small; Arthur W Toga; Jeffrey L Cummings; Michael E Phelps; Daniel H Silverman
Journal:  Mol Imaging Biol       Date:  2009-07-28       Impact factor: 3.488

5.  Synthesis and Purification of Highly Hydrophobic Peptides Derived from the C-Terminus of Amyloid β-Protein.

Authors:  M M Condron; B H Monien; G Bitan
Journal:  Open Biotechnol J       Date:  2008-01-01

6.  RNA aptamers generated against oligomeric Abeta40 recognize common amyloid aptatopes with low specificity but high sensitivity.

Authors:  Farid Rahimi; Kazuma Murakami; Jamie L Summers; Chi-Hong B Chen; Gal Bitan
Journal:  PLoS One       Date:  2009-11-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.